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Abstract
N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) lesions of the locus coeruleus (LC), the
major brain noradrenergic nucleus, exacerbate the damage to nigrostriatal dopamine (DA) terminals
caused by the psychostimulant methamphetamine (METH). However, because noradrenergic
terminals contain other neuromodulators and the noradrenaline (NA) transporter, which may act as
a neuroprotective buffer, it was unclear whether this enhancement of METH neurotoxicity was
caused by the loss of noradrenergic innervation or the loss of NA itself. We addressed the specific
role of NA by comparing the effects of METH in mice with noradrenergic lesions (DSP-4) and those
with intact noradrenergic terminals but specifically lacking NA (genetic or acute pharmacological
blockade of the NA biosynthetic enzyme dopamine β-hydroxylase; DBH). We found that genetic
deletion of DBH (DBH −/− mice) and acute treatment of wild-type mice with a DBH inhibitor (fusaric
acid) recapitulated the effects of DSP-4 lesions on METH responses. All three methods of NA
depletion enhanced striatal DA release, extracellular oxidative stress (as measured by in vivo
microdialysis of DA and 2,3-dihydroxybenzoic acid), and behavioural stereotypies following
repeated METH administration. These effects accompanied a worsening of the striatal DA neuron
terminal damage and ultrastructural changes to medium spiny neurons. We conclude that NA itself
is neuroprotective and plays a fundamental role in the sensitivity of striatal DA terminals to the
neurochemical, behavioural, and neurotoxic effects of METH.
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Introduction
Methamphetamine (METH) is a psychostimulant drug that is widely abused and causes long-
term neurotoxicity (Seiden et al., 1976; Kogan et al., 1976; Hotchkiss and Gibb, 1980; Ricaurte
et al., 1980). Neurotoxicity occurs in rodents (Schmidt et al., 1985; Sonsalla et al., 1985;
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Sonsalla and Heikkila 1988; Sonsalla et al., 1989; O'Callaghan and Miller, 1994; Albers and
Sonsalla, 1995; Fornai et al., 2004), as well as non-human primates (Seiden et al. 1976;
Villemagne et al. 1998), and humans (Wilson et al., 1996), leading to partially reversible
dopamine (DA) depletion (Volkow et al., 2001a), which is greater in the caudate than the
putamen nucleus (Wilson et al., 1996; McCann et al., 1998; Volkow et al., 2001a; Volkow et
al., 2001b; Fitzmaurice et al., 2006).
The noradrenaline (NA) system is generally neuroprotective and influences the vulnerability
of nigrostriatal DA neurons as shown by various neurotoxic models like 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP, Mavridis et al., 1991; Marien et al., 1993; Bing et
al., 1994; Fornai et al., 1995; Fornai et al., 1997a; Gesi et al., 2000) and 6-hydroxydopamine
(Srinivasan and Schmidt, 2003, 2004). Lesions of NA axons arising from the locus coeruleus
(LC) exacerbate the damage to DA neurons produced by METH in mice (Fornai et al., 1995;
Fornai et al., 1999). However, because these experiments were performed within the context
of damaged NA terminals, it is unclear whether the loss of NA terminals or NA itself is
deleterious. It has been suggested that the plasma membrane NA transporter (NET), which is
expressed by NA neurons and can take up METH, can act as a “buffer” by sequestering toxins
such as METH (Han and Gu, 2006) and MPTP away from DA neurons (Rommelfanger et al.,
2004). In addition, damage to NA neurons likely causes changes in the release of potential
neuroprotective noradrenergic co-transmitters such as neuropeptide Y and galanin (Yoshihara
et al., 1996). Thus, a specific role for endogenous NA itself remains questionable.
In addition to the influence on METH-induced neurotoxicity, a prominent role for NA in the
rewarding and addictive properties of DA-releasing drugs has also been described
(Weinshenker and Schroeder, 2007). For example, we found that mice specifically lacking NA
are hypersensitive to the behavioural effects of cocaine, but responses to METH were not tested
(Weinshenker et al., 2002; Schank et al., 2006).
In the present study we compared the neurochemical, behavioural, and neurotoxic effects
induced by different doses of METH in intact wild-type mice, N-(2-chloroethyl)-N-ethyl-2-
bromobenzylamine (DSP-4) treated mice with damaged noradrenergic terminals, dopamine
β-hydroxylase knockout (DBH −/−) mice that have structurally intact noradrenergic terminals
but specifically lack NA (Thomas et al., 1995; 1998), and in mice treated with the DBH inhibitor
fusaric acid. Specifically, we examined METH-induced DA release, METH-induced
behavioural effects, METH-induced oxidation and neurotoxicity as well as alterations of
ultrastructural morphology. The results of the present study enhance our understanding of the
neuroprotective interaction between NA and the nigrostriatal DA system, as well as the role
of endogenous NA in the neurochemical and behavioural effects of addictive DA-releasing
agents.
Materials and Methods
Animals
Male C57Bl mice (8 months old, N = 50) were purchased from Charles River (Calco, Italy).
Male DBH −/− mice (8−9 months old, N= 20), maintained on a mixed 129/SvEv and C57Bl6/
J background, were developed and generated at Emory University (Atlanta, GA, USA) as
previously described (Thomas et al., 1995; 1998). Because DBH is required for NA synthesis,
DBH −/− mice completely lack NA. Heterozygous (DBH +/−) mice have normal brain NA
levels and are indistinguishable from wild-type (DBH +/+) littermates for all previously tested
phenotypes, including MPTP toxicity (e.g. Thomas and Palmiter, 1997; Thomas et al., 1998;
Szot et al., 1999; Bourdelat-Parks et al., 2005; our unpublished data) and were therefore used
as controls for most experiments. As METH toxicity is sensitive to several environmental
parameters, mice were housed in stable and controlled conditions, consisting of constant room
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temperature (21°C), number of mice per cage (N= 5) and size of the cage (15 × 30 × 15 cm).
Mice were handled in accordance with the Policy on Humane care and Use of Laboratory
Animals of the United States Public Health Service. All the experiments were approved by the
Local Ethical Committee for Animal Studies.
Experimental groups and drug administration
The experimental protocol was designed to compare the effects produced by the absence of
NA per se with the damage of NA-containing axons. Therefore, saline or different doses of
METH were administered to untreated control mice 3 days following the systemic injection of
the neurotoxin DSP-4-hydrochloride (50 mg/kg; Sigma Chemical Co., St. Louis, MO, U.S.A.),
which selectively destroys LC-arising NA axons; 15 min after each administration of the DBH
inhibitor fusaric acid (40 mg/kg × 2, 2 h apart; Sigma), or to DBH −/− mice. In a pilot series
of experiments we measured NA levels at 1, 4, and 8 h following 4 different doses of fusaric
acid. Based on these experiments, the dose of fusaric acid of 40 mg/kg × 2, 2 h apart was
selected as the most effective in depleting brain NA in a variety of brain areas including the
striatum (Table I).
Immediately before and during METH administration (5 mg/ kg × 3, 2 h apart) 5 mice from
each group were used for the in vivo measurement of striatal extra-cellular levels of DA and
ROS by brain dialysis. These mice were then sacrificed 1 week later to measure striatal tissue
DA content, TH immunohistochemistry and striatal ultrastructure by electron microscopy.
Separate groups of mice (N=5 per group) were administered saline or METH (5 mg/kg × 1 or
5 mg/kg × 2) and were sacrificed after 1 week for the same assays. METH hydrochloryde
(Sigma), dissolved in saline solution, was administered intraperitoneally (i.p.). The doses of
METH refer to the free base and were selected based on previous studies to obtain a mild (low,
subtoxic dose) or severe (high, toxic dose) neurotoxic effect on DA nigrostriatal system (Fornai
et al., 1999; 2004; Battaglia et al., 2002). DSP-4 hydrochloryde and fusaric acid were dissolved
in distilled water and administered i.p.. Seven days after treatment, mice were sacrificed and
brain samples were processed either for biochemical or morphological analysis. Briefly, mice
were killed by decapitation and brains were quickly removed from the skull. For each mouse,
monoamine assays were carried out on brain samples collected from the right hemiencephalon,
whereas light microscopy and immunoblotting were performed on the left hemiencephalon
(see below).
Behavioral observations
Behavioral observations consisted of measurement of the locomotor activity in open field and
evaluation of stereotypies, such as licking and biting as defined by previous work (Seiden et
al. 1993). The open field box consisted of an 80 cm × 80 cm × 15 cm glassy holder, with the
floor divided into 64 squares (10 cm × 10 cm). For each mouse, locomotor activity was
measured by counting open field activity and rearing episodes. These were measured, daily,
by two independent, blind observers. In particular, open field activity was evaluated by the
number of squares crossed by the mice with all four legs during constant time intervals, each
lasting 2 min. Rearing behaviour (vertical movements) was evaluated using the same box with
transparent walls, with a normal, white floor. Rearing episodes were counted during periods
lasting 2 min and each episode was defined by the rearing of the mouse standing on the hind
limbs. Total observation period began 210 min before METH or saline administration and
continued for 420 min after first METH administrations. Specific behaviour was
simultaneously observed in order to describe the occurrence of different stereotypies and
locomotor activity during the same time interval. Data are shown as the means ± SEM of the
single values collected for each mouse belonging to the same group during a time interval of
1 h.
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Monoamine assay
Mice were sacrificed and their brains quickly removed to dissect the different brain areas
(striatum, and for the pilot experiments also the cerebellum, the hippocampus and the frontal
cortex) on a plate wheat of ice-cold saline. Briefly, the ice-cold dissected tissue was
homogenized with a sonicator. 50 μL was collected and processed to measure the protein
concentrations according to the Lowry's procedure, while the remaining 550 μL was
centrifuged, and 20 μL of the clear supernatant was immediately injected into HPLC. When
striatal dialysate samples were collected, 20 μL of the perfusate was directly injected into an
HPLC. The HPLC system consisted of an autosampler 507, a programmable solvent module
126, a C18 reverse-phase column (Beckmann Instruments, Fullerton, CA, USA) and a
Coulochem III with an analytical cell 5011A (ESA Inc. Chelmsford, MA, USA). NA, DA,
serotonin and metabolites were analyzed in a ion-pairing, reverse phase mode. The analytical
cell was composed of two electrodes the first working at +300 mV, and the second at −300
mV. The signal was recorded at both electrodes. Before and during the assay of the samples,
standard solutions were run in the system to build two regression curves (one for the oxidizing
and the other for the reducing electrode). On this basis, the striatal amount of DA was
determined by an absolute quantitative assay per protein unit (striatal homogenates) or
extracellular volume unit (striatal microdialysates).
Striatal microdialysis in freely moving mice
Mice were implanted with microdialysis intracerebral guides (CMA/7 Guide Cannula, CMA/
Microdialysis, Stockholm, Sweden). The site of implantation was left or right striatum
(coordinates in mm: AP = +0.6 from bregma; ML = ±1.7 lateral to the midline; DV = −2.5−4.5
from the surface of the skull, according to the atlas of Paxinos and Franklin 2004). Concentric
vertical microdialysis probes 2 mm long and 0.24 mm in outer diameter having a cuprophane
membrane with a molecular cut-off of 6000 Da (CMA/7 Microdialysis Probe, CMA/
Microdialysis) were used. The probes were perfused continuously with artificial cerebrospinal
fluid (ACSF), at a flow rate of 1.5 μL/min, using a microinjection pump (Bioanalytical System
Inc., West Lafayette, IN, USA). The ACSF contained 150 mmol/L NaCl, 3 mmol/L KCl, 1.7
mmol/L CaCl2, and 0.9 mmol/L MgCl2. This solution was not buffered, and the pH was
typically 6.5. After three sample fractions, used to determine the basal levels of striatal DA
and ROS, mice received three injections of METH (5 mg/kg, i.p., 2 h apart).
Measurement of reactive oxygen species (ROS)
Formation of ROS was examined by monitoring the amount of the product 2,3-
dihydroxybenzoic acid (2,3-DHBA), which is derived from the reaction of salicylate (5 mmol/
L, added to ACSF) with hydroxyl radicals occurring in the extracellular space. Thus, the
amount of 2,3-DHBA provides an indirect measure of the extracellular ROS levels (Giovanni
et al. 1995). Analysis of 2,3- DHBA was performed by HPLC with electrochemical detection
(Coulochem II electrochemical detectorESA, Inc., Chelmsford, MA, USA, as previously
published, Battaglia et al. 2002). The amount of 2,3-DHBA was expressed as percentage of
baseline values.
Morphological analysis and immunocytochemistry
The left brain hemisphere from each mouse was either frozen by immersion in cold isopentane
and stored at −80°C or immersed for 24 h in a fixative solution consisting of a buffered
formaline solution, containing 4% formaldehyde in phosphate buffer 0.1 mol/L. Fixed brains
were included in paraffin as described in Fornai et al. (1999).
For immunocytochemical experiments, frozen brains were cut on a cryostat (20 μm-thick
sections), and paraffin-embedded brains were cut on a microtome (5 μm-thick sections). In
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order to characterize monoaminergic innervation in specific brain areas, we used a primary
antibody directed against TH (Chemicon International, Temecula, CA, USA) at working
dilution of either 1:1000 (frozen slices) or 1:500 (paraffin-embedded slices), or against glial
fibrillary acidic protein (GFAP, 1:400, Chemicon). The secondary biotynilated antibodies (for
TH staining, Vector Laboratories, Burlingame, CA) were used at a dilution of 1:200, followed
by incubation with an ABC kit and diaminobenzydine (Vector Laboratories), whereas the
fluorescein-conjugated secondary antibody (for GFAP staining, Vector Laboratories) was used
at a dilution of 1:100.
SDS-Page Immunoblotting
The tissues were homogenized in buffer containing 50 mmol/L Tris-HCl (pH=7.5), 150 mmol/
L NaCl, 1 mmol/L EDTA, 1 mmol/L PMSF, 0.5% NP-40, 0.25% SDS and 10 μg/ml of protease
inhibitors (leupeptin, pepstatin, aprotinin; Sigma). Homogenates were centrifuged at 5,000g
for 5 min and the supernatant was subsequently centrifuged at 30,000g for 30 min (Rothman
et al., 2003). An aliquot of supernatant was used to determine the protein concentration by a
protein assay kit (Sigma). Samples containing 40 μg of total protein were dissolved and
electrophoresed on 12% sodium dodecyl sulfate-polyacrylamide gel. Following
electrophoresis, the proteins were transferred to PVDF membrane (Millipore, Bedford, MA,
USA). The membrane was immersed in blocking solution (5% not fat dried milk in 20 mmol/
L Tris, 137 mmol/L NaCl at pH 7.6 containing 0.05% Tween-20) for 3 h at 4°C. Subsequently,
the membrane was incubated with an anti-TH primary antibody (1:1000; Sigma) at 4°C
overnight. The blot was probed with horseradish peroxidase-labeled secondary antibody
(1:2000; Amersham Pharmacia Biotech, Buckinghamshire, UK) and TH bands were visualized
with enhanced chemiluminescence reagents (Amersham). Immunoreactive bands were
analyzed semi-quantitatively using densitometry (Lin et al., 1999). Films of western blots were
scanned by using Adobe Photoshop CS2 version 9.0 (Adobe Systems, Mountain View, CA),
and the optical density (OD) of the bands was measured by using NIH IMAGE 1.61. The
relative values of each immunoreactive band were calculated by subtracting the background
of the OD value from the measured OD of the bands. Groups used for statistical analyses were
always determined within the same western blot. The analysis was performed in triplicate for
confirmation of the results.
Electron microscopy
For electron microscopy, mice were perfused and the brain were immersed in fixing solution
(2% pformaldehyde/0.1% glutaraldehyde in 0.1 mol/L phosphate-buffered saline, pH 7.4)
overnight at 4°C. Brains were then removed, and the striatum was dissected and post fixed in
1% OsO4 in buffered solution, dehydrated in ethanol, and embedded in Epon-araldide.
Ultrathin sections were stained with uranyl acetate and lead citrate and were examined with a
Jeol (Tokyo, Japan) Jem 100SX transmission electron microscope.
Statistical analysis
For the locomotor activity (open field activity and rearing), each mouse was tested for 630 min
during drug administration, for periods lasting 2 min every 30 min. Results obtained by each
observer for each mouse were averaged for each count. The cumulative data were shown as
the mean ± SEM from groups of 5−7 mice. For the biochemical assay, results from each group
are expressed as the mean ± SEM of values obtained from each group of mice (N=5−7). All
data were compared between groups using one way ANOVA with Sheffè's post-hoc analysis.
The null hypothesis was rejected when p<0.05. To count the number of striatal cells with
whorls, we analysed electron microscopy samples. In particular, from each mouse (N=5) per
group, we randomly chose two tissue blocks dissected from dorso-lateral striatum. From each
block, we obtained 10 grids, each one containing several non-serial (for the striatum, size
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interval = 50 μm) slices in order to observe a total of 10 neurons. The number of the striatal
cells containing whorls, out of the total number of neurons under observation, were compared
using ANOVA with Sheffè's post hoc analysis. The null hypothesis was rejected when p<0.05.
Results
Fusaric acid induces a specific pattern of NA depletion
Tissue NA levels were measured in the striatum, hippocampus, frontal cortex and cerebellum
at various time intervals (1, 4, 8 h) after fusaric acid administration (20 mg/kg ×1 and ×2 or
40 mg/kg ×1 and ×2, 2 h apart, i.p.) (Table 1). A significant NA loss was detected in all areas
that reached the maximum effect 4 h after the drug administration. For the highest dose of
fusaric acid (40 mg/kg ×2) the depletion of NA was greater than 80% and was still evident
after 8 h.
NA depletion enhances METH-induced striatal DA release, locomotor activity, and
stereotypies
Baseline extracellular striatal DA levels were reduced by all three methods of NA depletion,
and reached significance for DSP-4 and in DBH −/− mice (Fig. 1). Administration of METH
(5 mg/kg × 3) produced a significant increase in extracellular striatal DA levels in control mice,
as measured by in vivo microdialysis, which was magnified by damage to NA axons elicited
3 days earlier by the neurotoxin DSP-4 (Fig. 1a). This effect of DSP-4 was, in general,
mimicked by selective NA depletion by pharmacological (fusaric acid; Fig. 1b) or genetic
(DBH −/− mice; Fig. 1c) inhibition of DBH. We did observe one discrepancy between the
effects produced by NA damage and the NA depletion (Fig. 1). While all paradigms reduced
baseline DA levels, extracellular DA levels were increased following all three METH
injections in DSP-4 treated mice compared to controls (Fig. 1a). In contrast, extracellular DA
levels were reduced in NA depleted mice following the first METH injection, then increased
following the second and third METH injections (Fig. 1b, 1c). The stimulation of DA release
was accompanied by an increase in open field activity, which reached the maximum in control
(wild-type and DBH +/−) mice soon after the first injection of METH (Fig. 2). This
hyperlocomotion showed a progressive decrease starting at about 3 h following the first METH
injection, remaining lower than baseline during the rest of the observation period. The onset
of decreased locomotor activity was concomitant with the increase of stereotyped behaviours
in most mice, and stereotypies were present in all mice following the second METH injection
(Fig. 3). Pre-treatment with fusaric acid and the DBH −/− mutation both reduced baseline
locomotor activity (30 min prior to METH administration; Fig. 2), as previously described (e.g.
Weinshenker et al., 2002), but had no effect on baseline stereotypies (Fig. 3). DSP-4 and fusaric
acid enhanced the initial METH-induced locomotor activity (Fig. 2a, 2b), while the locomotor
activity of DBH −/− mice started to decrease following the first METH injection, then remained
steady following the subsequent METH injections (Fig. 2c). All three NA depletion strategies
(DSP-4, fusaric acid, DBH −/− mice) significantly exacerbated the magnitude of METH-
induced stereotypies, and onset of stereotypies was faster in DBH −/− mice compared to DBH
+/− mice (Fig. 3c). These results are consistent with previous observations of stereotypies in
amphetamine-treated DBH −/− mice (Weinshenker et al., 2002). Following the third METH
injection, two DBH −/− mice experienced typical limbic seizures, which lasted for ∼ 30 min.
DBH −/− mice are known to be hypersensitive to many types of seizures elicited by various
chemoconvulsants, including kainic acid-induced limbic seizures (Szot et al.,
1999;Weinshenker et al., 2001). Interestingly, we also observe occasional limbic seizures in
mice pre-treated with fusaric acid (data not shown)
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NA depletion increases METH-induced extracellular ROS and exacerbates METH toxicity
METH treatment acutely increased the production of striatal extracellular ROS as measured
by 2,3 DHBA in dialysate, and this effect was even more pronounced in mice pre-treated with
DSP-4, fusaric acid, and in DBH −/− mice (Fig. 4). Interestingly, the effect of NA depletion
on the pattern of extracellular ROS levels was similar to that of extracellular DA levels, with
opposite effects of DSP-4 vs. fusaric acid and DBH −/− mice following the first but not second
or third METH injection. METH dose-dependently caused damage to DA terminals in the
striatum, as measured by reductions in tissue DA content (Fig. 5) and TH immunostaining
(Figs. 6a, 7a, and 8a) 1 week later. METH also increased striatal gliosis (immunofluorescence
for GFAP) (Fig. 6b, 7b, and 8b). All measures of toxicity were exacerbated by DSP-4 (Fig.
6a-d), fusaric acid (Fig. 7), and in DBH −/−mice (Fig. 8). No change in the number of nigral
neurons was observed (Fig. 6e-f). After METH treatment, cytoplasmic and nuclear whorls and
double membrane autophagic-like structures were observed in striatal neurons (Figs. 9a, 9b),
as we have previously described (Fornai et al., 2004). Strikingly, genetic or pharmacological
NA depletion produced these ultrastructural changes even in the absence of METH (Fig. 9c),
and slightly enhanced these morphological features following METH treatment (Figs. 9d, 9e).
Discussion
A specific loss of NA enhances the effects of METH
We have previously shown that damage to noradrenergic neurons using DSP-4 enhanced the
neurotoxic effects of METH (Fornai et al., 1995; 1997b; 1999). Noradrenergic terminals
possess METH uptake sites (the NA transporter), which could sequester METH away from
DA neurons. Loss of these uptake sites following DSP-4 lesions may result in the exposure of
DA axons to greater concentrations of METH. In addition, noradrenergic terminals contain co-
transmitters such as NPY and galanin, and loss of these neuromodulators could also contribute
to the enhanced METH-induced toxicity observed after DSP-4 lesion. Thus, it was unclear
whether the effects of DSP-4 lesions on METH toxicity were due to a loss METH uptake sites
and co-transmitters, or NA itself. A “buffering” role for NA terminals was previously
postulated for other DA neurotoxins such as MPP+, which could potentially be sequestered
away from DA neurons by NA axons, thereby decreasing its availability to DA neurons
(Herkenham et al., 1991; Di Chiara et al., 1992; Fornai et al., 1997a). However, data do not
support this hypothesis. We showed that peak striatal METH concentration is not changed by
LC lesions (Fornai et al., 1999), and mice with a genetic or pharmacological disruption of the
NA transporter are resistant, rather than hypersensitive, to MPTP toxicity (Rommelfanger et
al., 2004). We found that the effects of DSP-4 on METH-induced striatal DA release,
extracellular ROS production, DA terminal damage, gliosis, and formation of autophagic
vacuoles and multilamellar whorls in intrinsic striatal neurons were mimicked by selective
genetic or pharmacological blockade of NA synthesis. These results demonstrate that the
absence of endogenous NA per se increases the toxicity of METH to the DA system.
The effects of NA depletion on METH-induced DA release
The enhancement of DA release by NA depletion following multiple doses of METH was
somewhat unexpected given that NA facilitates DA neuron firing, and DA release induced by
other drugs is typically attenuated when NA signalling is blocked (reviewed by Weinshenker
and Schroeder, 2007). For example, we have previously shown that both basal and
amphetamine-evoked DA release is attenuated in the striatum of DBH −/− mice (Schank et al.,
2006). This discrepancy is likely due to the mechanism of METH-induced DA release and the
number of METH injections. Despite the fact that amphetamine is a DA releasing agent, its
ability to increase extracellular DA in vivo is largely impulse-dependent, and requires
noradrenergic innervation (e.g. Darracq et al., 1998; Ventura et al., 2004; Schank et al.,
2006). It is possible that, as opposed to amphetamine, METH-induced DA release in vivo has
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a significant impulse-independent component (e.g. Nishijima et al., 1996). We confirmed that
baseline DA release was reduced following all three methods of NA depletion, and DA release
was reduced following a single dose of METH in DBH −/− and fusaric acid-treated mice. It
was only after the second dose of METH that DA release was markedly enhanced in the absence
of NA activity. Because DBH inhibition increases DA production in noradrenergic terminals,
it is tempting to speculate that DA overflow coming from noradrenergic neurons can account
for this observation. However, this mechanism can be ruled out by our results with the DSP-4
lesioned mice, which do not produce extra DA in noradrenergic neurons but still show an
enhancement of METH-induced DA release. We propose the following model to explain the
enhancement of DA release produced by multiple METH injections following NA depletion.
NA exerts a neuroprotective effect on DA neurons. In NA-depleted mice, the first dose of
METH disrupts the structural integrity of DA terminals to a larger extent than in mice with
intact noradrenergic innervation, thus exposing intracellular pools of DA to the extracellular
environment upon subsequent METH injections. In support of this hypothesis, we found that
7 days following a single METH injection, striatal tissue DA levels were reduced in NA-
depleted mice but not control mice (Fig. 5). It is still unclear why DA release is enhanced
following the first METH injection in DSP-4 lesioned mice but not DBH −/− or fusaric acid-
treated mice. It is possible that the levels of LC co-transmitters that normally inhibit DA release,
such as galanin, are reduced by the DSP-4 lesion, whereas these inhibitory neuromodulators
remain intact in mice with a specific NA depletion (Tsuda et al., 1998; Weiss et al., 1998;
Weiss et al., 2005; our unpublished data).
The effects of NA depletion on METH-induced striatal damage
We observed not only damage to striatal DA terminals following METH administration, but
also alterations to intrinsic striatal medium spiny neurons as well. As originally hypothesized
by Jakel and Maragos (2000), high extracellular levels of DA within the striatal milieu may
affect the medium spiny neurons, either via DA receptors or through oxidative species. All
three methods we used to deplete NA enhanced the DA release and the production of
extracellular ROS produced by METH administration, and also worsened gliosis and the
abundance of striatal whorls. We recently found that the increase in extracellular striatal DA
levels is directly responsible, through the activation of D1-like DA receptors, for the
ultrastructural alterations in medium spiny neurons generated by METH, in the form of
autophagic vacuoles and multilamellar whorls (Lazzeri et al., 2007). Furthermore, we and
others have shown that in the absence of NA, there is a compensatory increase in the sensitivity
of striatal DA receptors (Donaldson et al., 1976; Lategan et al., 1990; Harro et al., 2000; Schank
et al., 2006). Although the stimulation of D1 receptors alone can reproduce the ultrastructural
changes triggered by DA (Lazzeri et al., 2007), this effect is modest compared with METH
administration. Thus, we hypothesize that a synergistic effect of extracellular ROS and DA
receptor stimulation on METH-induced damage to striatal medium spiny neurons takes place,
and that NA loss exacerbates both of these mechanisms.
Relationships between METH-neurotoxicity and neurodegeneration
Multiple degenerative disorders of the central nervous system, such as Parkinson's disease (PD)
and Alzheimer's disease, are characterized by the loss of NA neurons in the LC (Gesi et al.,
2000; Zarow et al., 2003; Marien et al., 2004; Rommelfanger and Weinshenker, 2007).
Experimental damage to LC neurons exacerbates the toxicity of a variety of DA neurotoxins,
including MPTP (Mavridis et al., 1991; Marien et al., 1993; Fornai et al., 1997), METH (Fornai
et al. 1995), 3,4-methylenedioxyamphetamine (MDMA) (Ferrucci et al., 2002), and 6-OHDA
(Srinivasan and Schmidt, 2003, 2004), indicating a protective role of this nucleus on the
survival of nigrostriatal DA neurons. A similar effect was recently substantiated by
pathological (Zarow et al., 2003) and biochemical (Tong et al., 2006) findings in humans. Our
results indicate that the protective effect of LC neurons against METH toxicity is at least
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partially, if not predominantly, mediated by NA itself, although a contribution of other
substances contained in NA neurons cannot be ruled out. Our findings have significant
implications for both METH addiction and the survival of the nigrostriatal DA system in PD.
An important role for the NA system in psychostimulant abuse is now emerging (reviewed by
Weinshenker and Schroeder, 2007), while the protective role of the NA system in PD has strong
support at pre-clinical and clinical levels. It should be considered that the pattern of nigrostriatal
DA denervation that occurs in PD differs from what is reported in long-term abstinent,
previously chronic METH abusers. For example, the pattern of striatal DA loss is more
pronounced in the putamen than the caudate nucleus of PD patients, while the opposite occurs
in METH abusers. The influence of METH on the caudate nucleus may partially underlie the
psychiatric symptoms that often occur in these patients (Volkow et al., 2001b). Moreover,
although still pronounced long after discontinuation of METH use, there is considerable
recovery from the nigrotriatal denervation in these patients (Volkow et al., 2001a), while PD
is characterized by irreversible DA neuronal death and disease progression. Nonetheless, NA
system involvement in PD and METH abuse may extend to other features of disease, including
the long-term side effects of the DA substitution therapy. For example, stereotyped abnormal
involuntary movement, which occurs as a consequence of chronic DA replacement therapy in
PD with L-3,4-dihydroxyphenylalanine (L-DOPA), occurs earlier and with greater severity
when NA neurons are damaged (Fulceri et al., 2007). Interestingly, such a behavioral effect is
accompanied by ultrastructural alterations within striatal neurons that are equivalent of those
occurring in NA-deficient mice following METH administration (Fulceri et al., 2007). It is
important to note that although the neuroprotective effects of NA in PD and METH toxicity
appear to be crucial, its precise mechanism of action remains elusive. NA could promote the
survival of DA neurons by activating neurotrophins such as NGF and BDNF (Semkowa and
Krieglstein, 1999). Alternatively, NA has been shown to possess potent antioxidant properties
and protects DA neurons from oxidative stress in vitro (Troadec et al., 2001). Finally, it should
be considered that noradrenergic innervation provides both excitatory and inhibitory drive onto
DA neurons. Thus, a direct receptor-mediated influence on midbrain DA neurons by NA and
subsequent changes in DA release and striatal signaling should be considered.
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Figure 1. NA depletion enhances METH-induced striatal DA release
Shown are striatal DA levels, as measured by microdialysis, in mice at baseline and following
METH administration (5 mg/kg ×3, 2 h apart; arrows) in (a) mice pretreated with DSP-4 (b)
mice pretreated with fusaric acid, and (c) in DBH −/− mice. Results were obtained from 5
animals per group and are expressed as mean ±SEM (bars) values. Differences among groups
were evaluated using ANOVA with Sheffè's post hoc analysis.
*p<0.05 compared with controls.
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Figure 2. NA depletion modifies METH-induced locomotor activity
Shown is locomotor activity, as measured by line crossings and rearing episodes in an open
field, at baseline or following METH administration (5 mg/kg ×3, 2 h apart; arrows) in (a)
mice pretreated with DSP-4, (b) mice pretreated with fusaric acid, and (c) DBH −/− mice.
Results were obtained from 5 animals per group and are expressed as mean ±SEM (bars) values.
Differences among groups were evaluated using ANOVA with Sheffè's post hoc analysis.
*p<0.05 compared with controls, §p<0.05 compared with METH.
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Figure 3. NA depletion enhances METH-induced stereotypes
Shown are the onset and frequency of stereotyped behaviours following METH administration
(5 mg/kg ×3, 2 h apart; arrows) in (a) mice pretreated with DSP-4, (b) mice pretreated with
fusaric acid, and (c) DBH −/− mice. Note that the appearance of stereotypies were concomitant
with the decrease in locomotor activity (see Fig. 2).
Results were obtained from 5 animals per group and are expressed as mean ±SEM (bars) values.
Differences among groups were evaluated using ANOVA with Sheffè's post hoc analysis.
*p<0.05 compared with controls, §p<0.05 compared with METH.
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Figure 4. NA depletion increases METH-induced extracellular radical oxygen species (ROS)
Shown is the formation of ROS, as assessed by striatal dialysate levels of 2,3-DHBA, following
METH administration (5 mg/kg ×3, 2 h apart; arrows) in (a) mice pretreated with DSP-4, (b)
mice pretreated with fusaric acid, and (c) DBH −/− mice. Results were obtained from 5 animals
per group and are expressed as mean ±SEM (bars) values. Differences among groups were
evaluated using ANOVA with Sheffè's post hoc analysis.
*p<0.05 compared with controls.
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Figure 5. NA depletion enhances METH-induced striatal DA loss
Shown are striatal tissue DA levels 7 days following saline or METH administration (5 mg/kg
×1, 5 mg/kg ×2, and 5 mg/kg ×3, 2 h apart) in (a) mice pretreated with DSP-4, (b) mice
pretreated with fusaric acid, and (c) DBH −/− mice. Results were obtained from 5 animals per
group and are expressed as the mean ±SEM. Differences among groups were evaluated using
ANOVA.
*p<0.05 compared with controls, §p<0.05 compared with METH.
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Figure 6. Effects of DSP-4 lesions on METH-induced toxicity
Mice were treated with saline, METH (5 mg/kg ×3, 2 h apart, i.p), DSP-4 (50 mg/kg, i.p.), or
DSP-4 + METH (METH was administered 3 days following DSP-4), and striata were analyzed
7 days later. Shown is (a) representative immunohistochemical analysis of striatal tyrosine
hydroxylase (TH), (b) representative immunohistochemical analysis of the glial marker GFAP
in striatum, (c) representative Western blot for striatal TH, (d) semiquantitative densitometry
of TH Western blot, and (e,f) representative analysis of TH immunoreactivity in the substantia
nigra.
Densitometry results were obtained from 3 experiments and are expressed as mean ±SEM
(bars) values. Differences among groups were evaluated using ANOVA with Sheffè's post hoc
analysis.
*p<0.05 compared with controls, §p<0.05 compared with METH.
Scale bars= 460 μm (a); 150 μm (b); 400 μm (e).
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Figure 7. Effects of fusaric acid treatment on METH-induced toxicity
Mice were treated with saline, METH (5 mg/kg ×3, 2 h apart, i.p), fusaric acid (40 mg/kg ×2,
2 h apart, i.p), or DSP-4 + fusaric acid, and striata were analyzed 7 days later. Shown is (a)
representative immunohistochemical analysis of striatal tyrosine hydroxylase (TH), (b)
representative immunohistochemical analysis of the glial marker GFAP in striatum, (c)
representative Western blot for striatal TH, and (d) semiquantitative densitometry of TH
Western blot.Densitometry results were obtained from 3 experiments and are expressed as
mean ±SEM (bars) values. Differences among groups were evaluated using ANOVA with
Sheffè's post hoc analysis.
Scale bars= 400 μm (a); 125 μm (b).
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Figure 8. METH-induced toxicity in DBH −/− mice
DBH +/− and DBH −/− mice were treated with saline or METH (5 mg/kg ×3, 2 h apart, i.p),
and striata were analyzed 7 days later. Shown is (a) representative immunohistochemical
analysis of striatal tyrosine hydroxylase (TH), (b) representative immunohistochemical
analysis of the glial marker GFAP in striatum, (c) representative Western blot for striatal TH,
and (d) semiquantitative densitometry of TH Western blot. Results were and are expressed as
mean ±SEM (bars) values. Differences among groups were evaluated using ANOVA with
Sheffè's post hoc analysis.
Scale bars= 400 μm (a); 115 μm (b)
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Figure 9. Effects of NA depletion on baseline and METH-induced whorls in striatal medium spiny
neurons
Mice were treated with saline or METH (5 mg/kg ×3, 2 h apart, i.p.), and striatal ultrastructure
was analyzed for the presence of membranous multilayer whorls in the cytoplasm (arrows) 7
days after METH treatment (5 mg/kg ×3, 2 h apart; a, b).
Similar morphological changes were produced following pharmacological depletion of NA
induced by DSP-4 in the absence of METH (c), this was slightly increased when METH was
administered to different kinds of NA depleted mice (d). Bar graphs show the number of
whorls-containing neurons for each experimental group (e).
Scale bars=0.56 μm (a); 0.14 μm (b); 0.42 μm (c); 0.2 μm (d)
Results were obtained from 5 animals per group and are expressed as mean ±SEM (bars) values.
Differences among groups were evaluated using ANOVA with Sheffè's post hoc analysis.
*p<0.05 compared with controls, §p<0.05 compared with METH.
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